Stretta In Reflux Uncontrolled by IPP (SIRUP)
Primary Purpose
Gastroesophageal Reflux Disease
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Stretta procedure
Sham procedure
Sponsored by
About this trial
This is an interventional treatment trial for Gastroesophageal Reflux Disease
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 ans
- Severe or moderate heartburn (at least 3 heartburn times per week), persistent under treatment with IPP
Exclusion Criteria:
- Recent oeso-gastro-duodenal endoscopy(< 3 months)
- Oesophagitis > grade A
- Endobrachyoesophagus > C0M1
- Hiatal Hernia > 2 cm
- Symptoms insufficiently relieved with continued intake of IPP or with intake of IPP according to needs
- Predominant symptom of Gastrooesophageal reflux disease other than heartburn
- Patients contra-indicated for radiofrequency technique
- Pregnant women
Sites / Locations
- Nantes Universitary Hospital
- Bordeaux Universitary Hospital
- Brest universitary hospital
- APHP - Louis Mourier hospital
- Lyon Universitary Hospital
- Rouen Universitary Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
Stretta procedure
Sham procedure
Arm Description
Patient randomized in Stretta procedure arm will be hospitalized to have endoscopy and esophagus will receive radiofrequency. Control visits will then take place until Month 6. At this visit endoscopic control will take place.
Patient randomized in Sham procedure arm will be hospitalized to have endoscopy. Material necessary to perform Stretta procedure will be inserted (like in Stretta procedure arm) BUT esophagus will not receive radiofrequency. Control visits will then take place until Month 6. At this visit endoscopic control will take place.
Outcomes
Primary Outcome Measures
Efficiency of the treatment 6 months post-procedure
Evaluate the efficiency of the treatment 6 months post-procedure according to the patient's answers to the 2 following items : IPP treatment taken less than 7 days /week and adequate relief of symptoms. These results will be completed by the patient on a calendar during 2 weeks before the visit week 24
Secondary Outcome Measures
Effects on digestive symptoms
Compare Stretta and sham procedure according to complete relief of digestive symptoms and pyrosis (calculation based upon number of days without digestive symptoms and pyrosis as indicated by the patient on a questionary completed during the 2 weeks preceding visits à 6 months)
Effects on digestive symptoms
Compare Stretta and sham procedure according to complete relief of digestive symptoms and pyrosis (calculation based upon number of days without digestive symptoms and pyrosis as indicated by the patient on a questionary completed during the 2 weeks preceding visits à 12 months)
Necessity of IPP treatment
Compare Stretta and sham procedure according to necessity of IPP treatment
necessity of IPP treatment
Compare Stretta and sham procedure according to necessity of IPP treatment
Tolerance
Compare Stretta and sham procedure according to Tolerance analysed by recording of adverse events (sides effects of each procedure) until week 24.
Tolerance
Compare Stretta and sham procedure according to Tolerance analysed by recording of adverse events (sides effects of each procedure) until week 48.
Quality of live
Compare Stretta and sham procedure according to Quality of life (use of quality of life questionaries)
Quality of life
Compare Stretta and sham procedure according to Quality of life
pH-impedancemetry predictive factors
pH-impedancemetry will be realized at clinical trial start, when patient is under PPI intake to determine pH-impedancemetry predictive factors for positive response to stretta method. Acid and non acid exposition of the esophagus will be measured as well as the SAP (Symptom Association Probability) which corresponds to the probability of association between symptoms felt by the patient during the pH-impedancemetry and episodes of acid or non acid reflux.
Efficiency
Evaluate efficiency of the stretta procedure in patients unsatisfied after the sham procedure at week 48 according to the patient's answers to the 2 following items : IPP treatment taken less than 7 days /week and adequate relief of symptoms. These results will be completed by the patient on a calendar during 2 weeks before the visit week 48
Efficiency
Evaluate efficiency of the 2nd stretta procedure in patients unsatisfied after the 1st stretta procedure at week 48 according to the patient's answers to the 2 following items : IPP treatment taken less than 7 days /week and adequate relief of symptoms. These results will be completed by the patient on a calendar during 2 weeks before the visit week 48
Full Information
NCT ID
NCT01682265
First Posted
September 5, 2012
Last Updated
January 28, 2019
Sponsor
Nantes University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01682265
Brief Title
Stretta In Reflux Uncontrolled by IPP
Acronym
SIRUP
Official Title
Stretta In Reflux Uncontrolled by Intake of Inhibitors of Protons Pump (IPP).- The SIRUP Trial- Multicentric, Randomized, Double Blind, Prospective Study
Study Type
Interventional
2. Study Status
Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
March 26, 2012 (Actual)
Primary Completion Date
November 27, 2018 (Actual)
Study Completion Date
November 27, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nantes University Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of the study is to compare the Stretta procedure and the Sham procedure efficiency 6months post-procedure in reflux uncontrolled by intake of Inhibitors of Protons Pump (IPP) patients.
Detailed Description
The study is over a period of 1 year. After checking eligibility, the patient will be randomised in double blind : stretta procedure /sham procedure. Control visits will take place after 4 weeks (on site), 8 weeks (by phone), 12 weeks (by phone), 18 weeks(on site) and 24 weeks(on site).During the 24 weeks visit, the therapeutic success will be evaluated.
In case of success, endoscopic control will be performed and the patient will come back on site at week 36 and 48 (end of study). In case of therapeutic failure, the stretta procedure will be proposed to the patient without breaking the blind for the 1st procedure. The procedure will be scheduled between week 24 and week 27. The patient will come back for a visit on site at weeks 31, 36 and 48 (end of visit)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastroesophageal Reflux Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
62 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Stretta procedure
Arm Type
Experimental
Arm Description
Patient randomized in Stretta procedure arm will be hospitalized to have endoscopy and esophagus will receive radiofrequency.
Control visits will then take place until Month 6. At this visit endoscopic control will take place.
Arm Title
Sham procedure
Arm Type
Sham Comparator
Arm Description
Patient randomized in Sham procedure arm will be hospitalized to have endoscopy. Material necessary to perform Stretta procedure will be inserted (like in Stretta procedure arm) BUT esophagus will not receive radiofrequency.
Control visits will then take place until Month 6. At this visit endoscopic control will take place.
Intervention Type
Other
Intervention Name(s)
Stretta procedure
Other Intervention Name(s)
Radiofrequency of esophagus
Intervention Type
Other
Intervention Name(s)
Sham procedure
Intervention Description
No radiofrequency delivered
Primary Outcome Measure Information:
Title
Efficiency of the treatment 6 months post-procedure
Description
Evaluate the efficiency of the treatment 6 months post-procedure according to the patient's answers to the 2 following items : IPP treatment taken less than 7 days /week and adequate relief of symptoms. These results will be completed by the patient on a calendar during 2 weeks before the visit week 24
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Effects on digestive symptoms
Description
Compare Stretta and sham procedure according to complete relief of digestive symptoms and pyrosis (calculation based upon number of days without digestive symptoms and pyrosis as indicated by the patient on a questionary completed during the 2 weeks preceding visits à 6 months)
Time Frame
6 months
Title
Effects on digestive symptoms
Description
Compare Stretta and sham procedure according to complete relief of digestive symptoms and pyrosis (calculation based upon number of days without digestive symptoms and pyrosis as indicated by the patient on a questionary completed during the 2 weeks preceding visits à 12 months)
Time Frame
1 year
Title
Necessity of IPP treatment
Description
Compare Stretta and sham procedure according to necessity of IPP treatment
Time Frame
6 months
Title
necessity of IPP treatment
Description
Compare Stretta and sham procedure according to necessity of IPP treatment
Time Frame
1 year
Title
Tolerance
Description
Compare Stretta and sham procedure according to Tolerance analysed by recording of adverse events (sides effects of each procedure) until week 24.
Time Frame
6 months
Title
Tolerance
Description
Compare Stretta and sham procedure according to Tolerance analysed by recording of adverse events (sides effects of each procedure) until week 48.
Time Frame
1 year
Title
Quality of live
Description
Compare Stretta and sham procedure according to Quality of life (use of quality of life questionaries)
Time Frame
6 months
Title
Quality of life
Description
Compare Stretta and sham procedure according to Quality of life
Time Frame
1 year
Title
pH-impedancemetry predictive factors
Description
pH-impedancemetry will be realized at clinical trial start, when patient is under PPI intake to determine pH-impedancemetry predictive factors for positive response to stretta method. Acid and non acid exposition of the esophagus will be measured as well as the SAP (Symptom Association Probability) which corresponds to the probability of association between symptoms felt by the patient during the pH-impedancemetry and episodes of acid or non acid reflux.
Time Frame
At Inclusion
Title
Efficiency
Description
Evaluate efficiency of the stretta procedure in patients unsatisfied after the sham procedure at week 48 according to the patient's answers to the 2 following items : IPP treatment taken less than 7 days /week and adequate relief of symptoms. These results will be completed by the patient on a calendar during 2 weeks before the visit week 48
Time Frame
1 year
Title
Efficiency
Description
Evaluate efficiency of the 2nd stretta procedure in patients unsatisfied after the 1st stretta procedure at week 48 according to the patient's answers to the 2 following items : IPP treatment taken less than 7 days /week and adequate relief of symptoms. These results will be completed by the patient on a calendar during 2 weeks before the visit week 48
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 ans
Severe or moderate heartburn (at least 3 heartburn times per week), persistent under treatment with IPP
Exclusion Criteria:
Recent oeso-gastro-duodenal endoscopy(< 3 months)
Oesophagitis > grade A
Endobrachyoesophagus > C0M1
Hiatal Hernia > 2 cm
Symptoms insufficiently relieved with continued intake of IPP or with intake of IPP according to needs
Predominant symptom of Gastrooesophageal reflux disease other than heartburn
Patients contra-indicated for radiofrequency technique
Pregnant women
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stanislas Bruley des Varannes, Professor
Organizational Affiliation
Nantes Universitary Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Chloe Melchior, Doctor
Organizational Affiliation
Rouen Universitary Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Thierry Ponchon, Professor
Organizational Affiliation
Lyon Universitary Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Franck Zerbib, Professor
Organizational Affiliation
Bordeaux Universitary Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Franck Cholet, Doctor
Organizational Affiliation
Brest Universitary hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Benoit Coffin, Professor
Organizational Affiliation
APHP-Louis Mourier hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nantes Universitary Hospital
City
Nantes
State/Province
Loire Atlantique
ZIP/Postal Code
44093
Country
France
Facility Name
Bordeaux Universitary Hospital
City
Bordeaux
Country
France
Facility Name
Brest universitary hospital
City
Brest
ZIP/Postal Code
29200
Country
France
Facility Name
APHP - Louis Mourier hospital
City
Colombes
ZIP/Postal Code
92700
Country
France
Facility Name
Lyon Universitary Hospital
City
Lyon
ZIP/Postal Code
69000
Country
France
Facility Name
Rouen Universitary Hospital
City
Rouen
ZIP/Postal Code
76000
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
32656869
Citation
Zerbib F, Sacher-Huvelin S, Coron E, Coffin B, Melchior C, Ponchon T, Cholet F, Chabrun E, Vavasseur F, Gorbatchef C, Zalar A, Mion F, Robaszkiewicz M, Le Rhun M, Leroy M, Paul Galmiche J, Bruley des Varannes S. Randomised clinical trial: oesophageal radiofrequency energy delivery versus sham for PPI-refractory heartburn. Aliment Pharmacol Ther. 2020 Aug;52(4):637-645. doi: 10.1111/apt.15936. Epub 2020 Jul 13.
Results Reference
derived
Learn more about this trial
Stretta In Reflux Uncontrolled by IPP
We'll reach out to this number within 24 hrs